Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 378 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Patches Clear all
Completed Phase 2 Interventional Results available

Synera Venipuncture Pain

NCT01744197
View directory record Official record
Conditions
Pain, Phlebotomy, Palliative Care
Interventions
Synera (lidocaine 70mg/tetracaine 70mg)
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Microneedle Patch Study in Healthy Infants/Young Children

NCT03207763
View directory record Official record
Conditions
Vaccination, Skin Absorption
Interventions
Microneedle Formulation 1, Microneedle Formulation 2
Device
Lead sponsor
Emory University
Other
Eligibility
6 Weeks to 24 Months
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study

NCT02312934
View directory record Official record
Conditions
Chemo Brain, Chemotherapy-related Cognitive Impairment, Chemo Fog, Breast Cancer, Chemobrain
Interventions
Transdermal nicotine, Placebo Transdermal Patch
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
35 Years to 80 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches

NCT04066023
View directory record Official record
Conditions
Cluster Headache
Interventions
C213 Microneedle System, Placebo
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lidocaine Patches Prior to Percutaneous Nerve Evaluation

NCT05783219
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Fecal Incontinence
Interventions
Lidocaine patch, Placebo
Drug · Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Flushing Reduction Associated With Nitrates

NCT02714205
View directory record Official record
Conditions
Menopausal Hot Flashes
Interventions
transdermal nitroglycerin, Placebo
Drug
Lead sponsor
Alison Huang, MD
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Oakland, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

NCT01544595
View directory record Official record
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
Secukinumab (AIN457), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Phase 2 Interventional

Depressed Mood Improvement Through Nicotine Dosing 3

NCT05746273
View directory record Official record
Conditions
Depressive Disorder
Interventions
Transdermal Nicotine Patch, Transdermal Placebo Patch
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 3, 2026, 7:29 AM EDT
Terminated Phase 2Phase 3 Interventional

Diclofenac Patch for Treatment of Mild to Moderate Ankle Sprain

NCT00640705
View directory record Official record
Conditions
Ankle Sprain
Interventions
diclofenac sodium, Matching placebo patch
Drug
Lead sponsor
Cerimon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2008 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Phase 3 Interventional

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

NCT00331123
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
20 Years to 70 Years · Female only
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 3, 2026, 7:29 AM EDT
Withdrawn Phase 2 Interventional

Trial to Evaluate the Efficacy of Topical Capsaicin to Reduce Pain and Improve Health-related Quality of Life in Adults With Chronic Myofascial Neck Pain

NCT00795106
View directory record Official record
Conditions
Myofascial Pain Syndrome
Interventions
Capsaicin, Placebo
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

Estrogen Receptor Beta and Mood

NCT03689543
View directory record Official record
Conditions
Perimenopause-Related Depression
Interventions
Estradiol, ER Beta Agonist, Placebo, Provera
Drug · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
45 Years to 65 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study

NCT00736255
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Nicotine Dependence
Interventions
Transdermal Nicotine Patch, Lis-dexamphetamine (Vyvanse), Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Sep 3, 2026, 7:29 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

NCT03838484
View directory record Official record
Conditions
Schizophrenia, Impulsive Behavior
Interventions
Nicotine Patch, 7 Mg/24 Hr, Placebo patch
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Phase 4 Interventional Results available

Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms

NCT00332644
View directory record Official record
Conditions
Nicotine Dependence
Interventions
nicotine patch, nicotine lozenge, nicotine patch + nicotine lozenge, bupropion, bupropion + lozenge, placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1,504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 29, 2011 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System vs Placebo in Children & Adolescents With ADHD

NCT01711021
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
d-Amphetamine Transdermal Patch, Placebo patch
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Irvine, California • Miami, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Phase 4 Interventional Results available

Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers

NCT01048944
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Bupropion SR, Nicotine Patch, Placebo Patch and Placebo Pill
Drug
Lead sponsor
Southern Illinois University Carbondale
Other
Eligibility
18 Years to 55 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Carbondale, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

Peanut Epicutaneous Phase II Immunotherapy Clinical Trial

NCT01904604
View directory record Official record
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Hypersensitivity, Hypersensitivity, Immediate
Interventions
Placebo Viaskin® Patch, Low-dose DBV712 Viaskin® Patch, High-dose DBV712 Viaskin® Patch
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 25 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2019 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Estrogen Variability and Irritability During the Menopause Transition

NCT05388656
View directory record Official record
Conditions
Menopause, Irritable Mood
Interventions
Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo, Progesterone 200 mg
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 59 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Results available

Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase

NCT01141283
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 75 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
42
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 3, 2026, 7:29 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Preemptive Use of the Nicotine Patch for Postoperative Pain Relief After Open Abdominal Surgery

NCT00790829
View directory record Official record
Conditions
Postoperative Pain
Interventions
transdermal nicotine patch
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Phase 1 Interventional

Use of Aromatherapy in Conjunction With Physical/Occupational Therapy in an Acute Care Setting

NCT05282706
View directory record Official record
Conditions
Suffering, Physical, Nausea
Interventions
Lavender Oil, Mandarin Oil, Peppermint oil, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Phase 4 Interventional

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

NCT00904202
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Complex Regional Pain Syndrome, Carpal Tunnel Syndrome, HIV Neuropathy, Idiopathic Sensory Neuropathy, Peripheral Neuropathy
Interventions
Placebo Capsules + Placebo Patch, Placebo capsules + Lidoderm®, Gabapentin + Placebo, Gabapentin + Lidoderm®, Gabapentin 300 mg capsules 1800 mg/day + placebo patch, Gabapentin 1800 mg/day + Lidoderm patch
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
7
States / cities
Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 3, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Results available

A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis

NCT01537042
View directory record Official record
Conditions
Restless Legs Syndrome, End-Stage Renal Disease
Interventions
Rotigotine, Placebo
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Brandon, Florida • Newton, Massachusetts • West Seneca, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Sep 3, 2026, 7:29 AM EDT